Application
EXT1 Antibody (Center) western blot analysis in K562 cell line lysates (35ug/lane).This demonstrates the EXT1 antibody detected the EXT1 protein (arrow).| Product Name | EXT1 Antibody (Center) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | EXT1; Exostosin-1; Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase; Multiple exostoses protein 1; Putative tumor suppressor protein EXT1 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | EXT1 Exostosin-1 Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase Multiple exostoses protein 1 Putative tumor suppressor protein EXT1 |
|---|---|
| Molecular Weight(MW) | 86255 Da |
| Function | Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone Appears to be a tumor suppressor |
| Tissue Specificity | Ubiquitous. |
| Cellular Localization | Endoplasmic reticulum membrane; Single-pass type II membrane protein. Golgi apparatus membrane; Single-pass type II membrane protein. Note=The EXT1/EXT2 complex is localized in the Golgi apparatus |
| Entrez Gene | 2131 |
|---|---|
| Nucleotide Accession | NP_000118.2 |
Application
EXT1 Antibody (Center) western blot analysis in K562 cell line lysates (35ug/lane).This demonstrates the EXT1 antibody detected the EXT1 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
